Actinium 225 PSMA Radioligand Therapy for Prostate Cancer | Saarland University Hospital

At the Saarland University Hospital (UKS), the nuclear medicine unit, under the leadership of Prof. S. Ezziddin, offers Actinium-225 PSMA radioligand therapy as a specialized last-line intervention for patients with metastatic castration-resistant prostate cancer. This advanced alpha-emitter therapy is specifically positioned for cases where standard treatments, including hormone therapy, chemotherapy, and even Lutetium-177 PSMA therapy, have failed to control the disease. The approach leverages the unique physical properties of Actinium-225, which delivers high-energy alpha radiation over an extremely short range, ensuring the destructive energy is concentrated within tumor cells while sparing surrounding healthy bone marrow and organ tissue. The therapeutic process at Homburg is deeply integrated with the clinic's world-class diagnostic infrastructure. Before treatment, patients undergo high-precision Ga-68 PSMA PET/CT scans accredited by the European Association of Nuclear Medicine. This imaging allows the medical team to visualize the exact density and location of PSMA-expressing lesions throughout the body, ensuring that the Actinium-225 molecules will effectively "home in" on every metastatic site. Because the department is one of the world's leading centers for molecular radiotherapy, the dosing and administration protocols are refined by extensive clinical experience, focusing on achieving a significant reduction in prostate-specific antigen levels while managing the side effects common to alpha-therapy, such as xerostomia. Beyond the technical administration of the radiopharmaceutical, the offer at Saarland University Hospital includes comprehensive inpatient care within Southwest Germany’s largest nuclear medicine facility. The treatment is typically delivered in several cycles, spaced several weeks apart, allowing for continuous monitoring of the patient's renal and hematological health. This structured environment ensures a seamless transition from diagnosis to therapy, providing a highly personalized treatment path for patients who require the most potent form of targeted radionuclide therapy currently available in modern oncology.